Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone

Bone

Volumn 73, Issue , 2015, Pages 8-15

  Saito, Mitsuru ^a   Grynpas, Marc D ^b   Burr, David B ^c   Allen, Matthew R ^c   Smith, Susan Y ^d   Doyle, Nancy ^d   Amizuka, Norio ^e   Hasegawa, Tomoka ^e   Kida, Yoshikuni ^a   Marumo, Keishi ^a   Saito, Hitoshi ^f  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MOUNT SINAI HOSPITAL   (Canada)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHARLES RIVER LABORATORIES   (United States)

^e HOKKAIDO UNIVERSITY   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bone microarchitecture; Bone microdamage; Bone mineralization; Bone quality; Collagen crosslinks; Vitamin D

Indexed keywords

COLLAGEN; ELDECALCITOL; VITAMIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACKSCATTERED ELECTRON MICROSCOPY; BONE DENSITY; BONE INJURY; BONE MINERALIZATION; BONE QUALITY; BONE REMODELING; BONE STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; ELECTRON MICROSCOPY; FEMALE; HISTOPATHOLOGY; LUMBAR VERTEBRA; MACACA FASCICULARIS; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PROTEIN CROSS LINKING; TRABECULAR BONE; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; BONE; DRUG EFFECTS; METABOLISM; ULTRASTRUCTURE;

ANIMALS; BONE AND BONES; CALCIFICATION, PHYSIOLOGIC; COLLAGEN; FEMALE; MACACA FASCICULARIS; MICROSCOPY, ELECTRON; VITAMIN D;

EID: 84919618979     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.11.025     Document Type: Article

References (46)

1. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006, 354:2250-2261.
2. Manolagas S.C., Almeida M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol 2007, 21:2605-2614.
3. Saito M., Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010, 21:195-214.
4. Uchiyama Y., Higuchi Y., Takeda S., Masaki T., Shira-Ishi A., Sato K., et al. ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 2002, 30:582-588.
5. Sakai S., Endo K., Takeda S., Mihara M., Shiraishi A. Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 2012, 50:1054-1063.
6. Smith S.Y., Doyle N., Boyer M., Chouinard L., Saito H. Eldecalcitol, a vitamin D analog, reduces bone turnover and increases trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone 2013, 57:116-122.
7. Harada S., Mizoguchi T., Kobayashi Y., Nakamichi Y., Takeda S., Sakai S., et al. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. J Bone Miner Res 2012, 27:461-473.
8. de Freitas P.H., Hasegawa T., Takeda S., Sasaki M., Tabata C., Oda K., et al. Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 2011, 49:335-342.
9. Kikuta J., Kawamura S., Okiji F., Shirazaki M., Sakai S., Saito H., et al. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc Natl Acad Sci U S A 2013, 110:7009-7013.
10. Matsumoto T., Ito M., Hayashi Y., Hirota T., Tanigawara Y., Sone T., et al. A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures-a randomized, active comparator, double-blind study. Bone 2011, 49:605-612.
11. Ito M., Nakamura T., Fukunaga M., Shiraki M., Matsumoto T. Effect of eldecalcitol, an active vitamin D analog, on hip structure and biomechanical properties: 3D assessment by clinical CT. Bone 2011, 49:328-334.
12. Hagino H., Takano T., Fukunaga M., Shiraki M., Nakamura T., Matsumoto T. Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis. J Bone Miner Metab 2013, 31:183-189.
13. Matsumoto T., Takano T., Saito H., Takahashi F. Vitamin D analogs and bone: preclinical and clinical studies with eldecalcitol. Bonekey Rep 2014, 3:513. 10.1038/bonekey.2014.8.
14. Jerome C.P., Peterson P.E. Nonhuman primate models in skeletal research. Bone 2001, 29:1-6.
15. Smith S.Y., Jolette J., Turner C.H. Skeletal health: primate model of postmenopausal osteoporosis. Am J Primatol 2009, 71:752-765.
16. Saito M., Marumo K., Kida Y., Ushiku C., Kato S., Takao-Kawabata R., et al. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1-34) for 18months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos Int 2011, 22:2373-2383.
17. Saito M., Fujii K., Mori Y., Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in the spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006, 17:1514-1523.
18. Wang X., Shen X., Li X., Agrawal C.M. Age-related changes in the collagen network and toughness of bone. Bone 2002, 31:1-7.
19. Oxlund H., Barckman M., Ortoft G., Andreassen T.T. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 1995, 17:365S-371S.
20. Banse X., Sims T.J., Bailey A.J. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 2002, 17:1621-1628.
21. Saito M., Shiraishi A., Ito M., Sakai S., Hayakawa N., Mihara M., et al. Comparison of effects of alfacalcidol and alendronate on mechanical properties and bone collagen cross-links of callus in the fracture repair rat model. Bone 2010, 46:1170-1179.
22. Saito M., Mori S., Mashiba T., Komatsubara S., Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008, 19:1343-1354.
23. Vashishth D., Gibson G.J., Khoury J.I., Schaffler M.B., Kimura J., Fyhrie D.P. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001, 28:195-201.
24. Tang S.Y., Zeenath U., Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 2007, 40:1144-1151.
25. Saito M., Marumo K., Soshi S., Kida Y., Ushiku C., Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int 2010, 21:655-666.
26. Nojiri H., Saita Y., Morikawa D., Kobayashi K., Tsuda C., Miyazaki T., et al. Cytoplasmic superoxide causes bone fragility due to low-turnover osteoporosis with impaired collagen cross-linking. J Bone Miner Res 2011, 26:2682-2694.
27. Saito M., Marumo K., Fujii K., Ishioka N. Single-column high-performance liquid chromatographic-fluorescence detection of immature, mature, and senescent cross-links of collagen. Anal Biochem 1997, 253:26-32.
28. Saito M., Kida Y., Kato S., Marumo K. Diabetes, collagen, and bone quality. Curr Osteoporos Rep 2014, 12:181-188.
29. Saito M., Fujii K., Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006, 79:160-168.
30. Saito M., Fujii K., Soshi S., Tanaka T. Reductions in degree of mineralization and enzymatic cross-links and increases in glycation-induced pentosidine in the femoral neck cortex in cases of femoral neck fracture. Osteoporos Int 2006, 17:986-995.
31. Sodek K.L., Tupy J.H., Sodek J., Grynpas M.D. Relationship between bone protein and mineral in developing porcine long bone and calvaria. Bone 2000, 26:189-198.
32. Lundon K., Dumitriu M., Grynpas M.D. Supraphysiologic levels of testosterone affect cancellous and cortical bone in the young female cynomolgus monkey. Calcif Tissue Int 1997, 60:54-62.
33. Grynpas M.D., Hunter G.K. Bone mineral and glycosaminoglycans in newborn and mature rabbits. J Bone Miner Res 1988, 3:159-164.
34. Allen M.R., Iwata K., Phipps R., Burr D.B. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 2006, 39:872-879.
35. Tang S.Y., Allen M.R., Phipps R., Burr D.B., Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009, 20:887-894.
36. Bracci P.M., Bull S.B., Grynpas M.D. Analysis of compositional bone density data using log ratio transformations. Biometrics 1998, 54:337-349.
37. Karim L., Tang S.Y., Sroga G.E., Vashishth D. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos Int 2013, 24:2441-2447.
38. Saito H., Takeda S., Amizuka N. Eldecalcitol and calcitriol stimulates 'bone minimodeling', focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol 2013, 136:178-182.
39. Itoh F., Kojima M., Furihata-Komatsu H., Aoyagi S., Kusama H., Komatsu H., et al. Reductions in bone mass, structure, and strength in axial and appendicular skeletons associated with increased turnover after ovariectomy in mature cynomolgus monkeys and preventive effects of clodronate. J Bone Miner Res 2002, 17:534-543.
40. Smith S.Y., Recker R.R., Hannan M., Müller R., Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 2003, 32:45-55.
41. Mori H., Tanaka M., Kayasuga R., Masuda T., Ochi Y., Yamada H., et al. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone 2008, 43:840-848.
42. Paschalis E.P., Shane E., Lyritis G., Skarantavos G., Mendelsohn R., Boskey A.L. Bone fragility and collagen cross-links. J Bone Miner Res 2004, 19:2000-2004.
43. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000, 15:613-620.
44. Yamauchi M. Collagen biochemistry: an overview 2002, World Scientific Publishing, Singapore.
45. Nagaoka H., Mochida Y., Atsawasuwan P., Kaku M., Kondoh T., Yamauchi M. 1,25(OH)2D3 regulates collagen quality in an osteoblastic cell culture system. Biochem Biophys Res Commun 2008, 377:674-678.
46. Nagaoka H., Terajima M., Yamada S., Azuma Y., Chida T., Yamauchi M. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res 2014, 32:1030-1036.